Trial reportThe pharmacogenomics journal2012
Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design.
Trial report in The pharmacogenomics journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01006733 (Genetics Informatics Trial), which is not on this map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Genetics Informatics Trial (GIFT) of Warfarin to Prevent Deep Venous Thrombosis (DVT)
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.Clinical pharmacology and therapeutics · 2017Guideline
- Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin.Chest · 2015Pooled it
- Trial
- Trial
- Use of signals and systems engineering to improve the safety of warfarin initiation.Journal of thrombosis and thrombolysis · 2016Trial
- A pharmacogenetic versus a clinical algorithm for warfarin dosing.The New England journal of medicine · 2013Trial
- Precision dosing of warfarin: open questions and strategies.The pharmacogenomics journal · 2019Review
- Genetic Testing in Clinical Settings.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2018Review
- Pharmacological and Non-pharmacological Treatments for Stroke Prevention in Patients with Atrial Fibrillation.Advances in therapy · 2017Review
- Contrasting Medical and Legal Standards of Evidence: A Precision Medicine Case Study.The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics · 2016Article
- Myocardial ischaemia after hip and knee arthroplasty: incidence and risk factors.International orthopaedics · 2015Article
- Pharmacogenomics of hypertension and heart disease.Current hypertension reports · 2015Review
- Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.Pharmacogenetics and genomics · 2015Article
- The use of warfarin for DVT prophylaxis following hip and knee arthroplasty: how often are patients within their target INR range?The Journal of arthroplasty · 2015Article
- Warfarin pharmacogenetics.Trends in cardiovascular medicine · 2015Review
- Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.British journal of clinical pharmacology · 2014Review
- Warfarin pharmacogenetic trials: is there a future for pharmacogenetic-guided dosing?Pharmacogenomics · 2014Article
- Review
- Pharmacogenetics in clinical pediatrics: challenges and strategies.Personalized medicine · 2013Article
- Pharmacogenetic testing: Current Evidence of Clinical Utility.Therapeutic advances in drug safety · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The risk of venous thromboembolism (VTE) is higher after the total hip or knee replacement surgery than after almost any other surgical procedure; warfarin sodium is commonly prescribed to reduce this peri-operative risk. Warfarin has a narrow therapeutic window with high inter-individual dose variability and can cause hemorrhage. The genetics-informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT) is a 2 × 2 factorial-design, randomized controlled trial designed to compare the safety and effectiveness of warfarin-dosing strategies. GIFT will answer two questions: (1) does pharmacogenetic (PGx) dosing reduce the rate of adverse events in orthopedic patients; and (2) is a lower target international normalized ratio (INR) non-inferior to a higher target INR in orthopedic participants? The composite primary endpoint of the trial is symptomatic and asymptomatic VTE (identified on screening ultrasonography), major hemorrhage, INR ≥ 4, and death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.